Literature DB >> 25581683

Natural products as zinc-dependent histone deacetylase inhibitors.

Shuai Tan1, Zhao-Peng Liu.   

Abstract

Zinc-dependent histone deacetylases (HDACs), a family of hydrolases that remove acetyl groups from lysine residues, play an important role in the regulation of multiple processes, from gene expression to protein activity. The dysregulation of HDACs is associated with many diseases including cancer, neurological disorders, cellular metabolism disorders, and inflammation. Molecules that act as HDAC inhibitors (HDACi) exhibit a variety of related bioactivities. In particular, HDACi have been applied clinically for the treatment of cancers. Inhibition through competitive binding of the catalytic domain of these enzymes has been achieved by a diverse array of small-molecule chemotypes, including a number of natural products. This review provides a systematic introduction of natural HDACi, with an emphasis on their enzyme inhibitory potency, selectivity, and biological activities, highlighting their various binding modes with HDACs.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antitumor agents; histone deacetylases; inhibitors; natural products; selectivity

Mesh:

Substances:

Year:  2015        PMID: 25581683     DOI: 10.1002/cmdc.201402460

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  3 in total

1.  HDACi and Nrf2: not from alpha to omega but from acetylation to OA.

Authors:  Holger Jahr
Journal:  Arthritis Res Ther       Date:  2015-12-18       Impact factor: 5.156

Review 2.  HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis.

Authors:  Xing Lyu; Min Hu; Jieting Peng; Xiangyu Zhang; Yan Y Sanders
Journal:  Ther Adv Chronic Dis       Date:  2019-07-18       Impact factor: 4.970

3.  The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.

Authors:  Hang Lu; Xue-Feng Yang; Xiao-Qing Tian; Shou-Long Tang; Lian-Qian Li; Shuang Zhao; Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2016-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.